As with NSCLC, in which TPS with cut‐off value of 50% is adopted for clinical use of PD‐1 inhibitors, future studies will determine optimal organ‐specific cut‐off values of PD‐L1 expression in GI cancer. The gene discussed is CD274; the disease is non-small cell lung carcinoma.